Search
Immutep Ltd
IMMPAdd to Watchlist
3.340USD
+0.650+24.16%
Close 11-06 16:00（ET）
24.61MMarket Cap
LossP/E TTM
Pre-market 06:57 (ET)3.600USD+0.260+7.78%
Pre-market 06:57 (ET)About Immutep Ltd Company
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Immutep Ltd Profile
Ticker SymbolIMMP
Company nameImmutep Ltd
IPO dateJun 23, 1988
CEOVoigt (Marc)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endJun 23
AddressLevel 32, Suite 32.07 Australia Square
CitySYDNEY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code2000
Phone61283157003
Websitehttps://www.immutep.com/
Ticker SymbolIMMP
IPO dateJun 23, 1988
CEOVoigt (Marc)
Company Executives of Immutep Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Marc Voigt
Mr. Marc Voigt
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
2.00
--
Mr. Marc Voigt
Mr. Marc Voigt
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
2.00
--
Ms. Deanne Miller
Ms. Deanne Miller
Chief Operating Officer, General Counsel, Joint Company Secretary
Chief Operating Officer, General Counsel, Joint Company Secretary
--
--
Dr. Russell John Howard, Ph.D.
Dr. Russell John Howard, Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Prof. Frederic Triebel, M.D., Ph.D.
Prof. Frederic Triebel, M.D., Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Ms. Indira Naidu
Ms. Indira Naidu
Joint Company Secretary
Joint Company Secretary
--
--
Ms. Lis (Elisabeth) Boyce
Ms. Lis (Elisabeth) Boyce
Non-Executive Director
Non-Executive Director
--
--
Dr. Stephan Winckels
Dr. Stephan Winckels
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Christian Mueller
Mr. Christian Mueller
Chief Development Officer
Chief Development Officer
--
--
Ms. Eleanor Pearson
Ms. Eleanor Pearson
Investors Relation
Investors Relation
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Marc Voigt
Mr. Marc Voigt
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
2.00
--
Mr. Marc Voigt
Mr. Marc Voigt
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
2.00
--
Ms. Deanne Miller
Ms. Deanne Miller
Chief Operating Officer, General Counsel, Joint Company Secretary
Chief Operating Officer, General Counsel, Joint Company Secretary
--
--
Dr. Russell John Howard, Ph.D.
Dr. Russell John Howard, Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Prof. Frederic Triebel, M.D., Ph.D.
Prof. Frederic Triebel, M.D., Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Ms. Indira Naidu
Ms. Indira Naidu
Joint Company Secretary
Joint Company Secretary
--
--
FAQs
Who are the top five shareholders of Immutep Ltd?
The top five shareholders of Immutep Ltd are: Mr. Marc Voigt
How many institutions hold shares of Immutep Ltd (IMMP)?
As of 2026Q1, 59 institutions hold shares of Immutep Ltd, with a combined market value of approximately 3.75M, accounting for 2.54% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -339406.00.